Form 4: Abbott Laboratories Director Acquires Stock Equivalent Units

Director Robert J. Alpern acquired 59 stock equivalent units in Abbott Laboratories through director fees credited to a grantor trust.

Summary

• Robert J. Alpern, a director of Abbott Laboratories, acquired 59 stock equivalent units on March 31, 2025.
• These units were credited to a stock equivalent unit account under a grantor trust.
• The director fees are paid in cash generally at age 65 or upon retirement from the board.
• The stock equivalent units earn the same return as if the fees were invested in Abbott shares.
• The price of the stock equivalent units was $132.65.
• Following the transaction, Alpern beneficially owns 10,093 stock equivalent units.
• This balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard director compensation practices and alignment with shareholder interests.

Industry Context

This filing reflects routine compensation practices for board members, aligning their interests with shareholders through equity-based compensation.

Stakeholder Impact

• The transaction aligns the director's interests with those of shareholders.
• The compensation structure may influence director decision-making to focus on long-term shareholder value.

Key Dates

Keywords

Abbott Laboratories, Stock Equivalent Units, Director Fees, Grantor Trust, Beneficial Ownership, Form 4, Alpern, ABT